Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Beat The Street With SI Traders -- Ignore unavailable to you. Want to Upgrade?

To: marcos who wrote (1507)	7/27/2009 3:00:32 PM
From: Rocket Red	Read Replies (1) \| Respond to of 233843

testing 60 types of cancer too :)))))))))))))

To: marcos who wrote (1507)	7/27/2009 3:06:36 PM
From: Condor	Read Replies (1) \| Respond to of 233843

GAP.v +++++++++++++++++++++++++++++++++++++++++++ News Story PharmaGap cancer treatment results on tap By Elizabeth Howell, Ottawa Business Journal Staff Fri, Jul 17, 2009 8:00 AM EST A day after announcing a $114,720 infusion of fundraised finances to fuel its cancer drug candidate, Ottawa-based PharmaGap Inc. (TSX-V:GAP) further stated it will release its first test results at some point next month. The pharmaceutical company is putting PhG-alpha-1 through its paces at the Ottawa Hospital Research Institute and the U.S. National Cancer Research Institute (NCI). The Ottawa Hospital's results on ovarian cancer cell treatment will be released during the first week of August, with the institute also planning to ramp up its test program to a second phase examining PhG-alpha-1's effectiveness in slowing ovarian cancer cell invasion and mobility. Later that month, the NCI will release its analysis on the drug's ability to treat a variety of cancers ranging from breast, to kidney, to leukemia.

To: marcos who wrote (1507)	7/27/2009 3:07:04 PM
From: ogi	Read Replies (1) \| Respond to of 233843

Not expecting much from CN, my cost is higher than yours @ .19, I have not averaged down as much :) ? Still not a big float with CN, so won't take too much to move it despite the recent give away. Gap, I don't dare hope for what could happen to the price, just sitting tight on virtually free shares and assuming the voyeur attitude! SSL. no forgotten that one, a long term solid deal. I have met Andrew Swarthout a couple of times re: Bear Creek and found him an exceptional individual and embraced as genuine by fellow geologists. Lots of shares, thin trader. Must add to my list Thanks.